Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Peter Kraft, Ph.D.

Co-Author

This page shows the publications co-authored by Peter Kraft and Adam Kibel.
Connection Strength

1.142
  1. Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer. J Natl Cancer Inst. 2021 Apr 01.
    View in: PubMed
    Score: 0.239
  2. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol. 2014 Jun; 65(6):1069-75.
    View in: PubMed
    Score: 0.145
  3. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 Mar; 53(3):413.
    View in: PubMed
    Score: 0.059
  4. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 01; 53(1):65-75.
    View in: PubMed
    Score: 0.059
  5. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2019 02; 51(2):363.
    View in: PubMed
    Score: 0.051
  6. Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 01 25; 10(1):431.
    View in: PubMed
    Score: 0.051
  7. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2019 01 17; 10(1):382.
    View in: PubMed
    Score: 0.051
  8. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun. 2018 11 05; 9(1):4616.
    View in: PubMed
    Score: 0.051
  9. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018 07; 50(7):928-936.
    View in: PubMed
    Score: 0.049
  10. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat Commun. 2018 06 11; 9(1):2256.
    View in: PubMed
    Score: 0.049
  11. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016 12; 53(12):800-811.
    View in: PubMed
    Score: 0.044
  12. Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discov. 2016 09; 6(9):1052-67.
    View in: PubMed
    Score: 0.043
  13. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nat Commun. 2016 Apr 07; 7:10979.
    View in: PubMed
    Score: 0.042
  14. Genome-wide association study of prostate cancer-specific survival. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1796-800.
    View in: PubMed
    Score: 0.041
  15. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014 Oct; 46(10):1103-9.
    View in: PubMed
    Score: 0.038
  16. Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. PLoS Genet. 2014 Feb; 10(2):e1004129.
    View in: PubMed
    Score: 0.036
  17. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013 Apr; 45(4):385-91, 391e1-2.
    View in: PubMed
    Score: 0.034
  18. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet. 2013 Jun 15; 22(12):2520-8.
    View in: PubMed
    Score: 0.034
  19. Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet. 2008 Sep; 40(9):1032-4; author reply 1035-6.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.